Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

http://www.wikidata.org/entity/Q39308923

about

Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis Clinicopathologic Significance and Prognostic Value of B7 Homolog 1 in Gastric Cancer: A Systematic Review and Meta-Analysis Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Development of Novel Immunotherapies for Multiple Myeloma Mesenchymal Stromal Cells Can Regulate the Immune Response in the Tumor Microenvironment Novel therapeutic strategies for multiple myeloma Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Checkpoint inhibitors in hematological malignancies Survivin-specific CD4+ T cells are decreased in patients with survivin-positive myeloma.Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.Enhancing cytokine-induced killer cell therapy of multiple myeloma.APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma.Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma.The targeting of immunosuppressive mechanisms in hematological malignancies.Targeting the bone marrow microenvironment in multiple myeloma.Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.Novel Immunotherapies for Multiple Myeloma.The potential diagnostic power of extracellular vesicle analysis for multiple myeloma.PD-L1-specific T cells.Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future.Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.Anti-regulatory T cells.Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma.Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.Microenvironment drug resistance in multiple myeloma: emerging new players.Targeting the Bone Marrow Microenvironment.PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.Bone marrow micro-environment is a crucial player for myelomagenesis and disease progression.Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression The multi-faceted potential of CD38 antibody targeting in multiple myeloma.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma.Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.

P2860

Q26775460-1776A539-1BD1-4B84-AB00-4EFCAC48BE4F Q26778025-9E54993E-7D80-4E1C-BD06-1B0555B0D074 Q26823660-F1C494E0-8E18-4AF7-948F-6CC862023BED Q27692033-20337D1A-4279-47ED-A830-07FDCE4EC1D2 Q28066890-688978EF-EAC5-405A-8095-460CFD6D4334 Q28073613-55E22BFC-54AE-4FFA-854C-95A5B8D00FD0 Q28081590-22CF792E-7BEB-43D4-8515-50DE31A12540 Q33638083-EC1121F2-A40E-4A5D-B24F-08076EFB2F9A Q33651495-3C211020-7337-4CB3-A8D2-427E7CCB0FD0 Q35623772-A26EF905-8355-4324-A87E-16C2A8670CBF Q36813010-5FAB7049-29CB-4A55-AA77-2EEDF5A703BD Q36892290-B0312ECB-316C-4240-A8B2-06A82C03CC01 Q37035836-F440F38B-6672-4B14-AA5F-E2243B0A934F Q37381288-4E87AAFE-D797-4F4F-B818-F2E059BE85EB Q37462524-1A254185-32FD-4109-B110-698898881A4D Q37641801-83BDC7EB-C822-417A-9593-9157EA6BC331 Q38155039-D15C76B5-D89F-4690-A092-E8D5B95A80A3 Q38201231-9A312ABC-7015-4D20-86F8-A12FE798E38C Q38289041-4863FB73-4D5B-4D84-BD80-6F3767E0F06B Q38370539-A2FF4E5E-9C06-47FA-9AC6-C06B41F711D5 Q38640444-E23CDAD1-3BEF-4833-A6DE-00E0704E940B Q38670495-84894E00-3037-4B98-87EA-690225456A68 Q38685359-20F7EA82-2D47-4590-9FFC-B34316D81789 Q38704573-4008C753-9621-450F-A48C-E113EDA2D956 Q38765760-53666F1D-4202-4381-83ED-2F5E4153A790 Q38792725-AFD0A74A-B7C1-426B-9183-3932E9484ABC Q38817090-01F9D73A-0621-4B26-8D46-BA7679A534A9 Q38853857-B758D44F-521D-46CE-A813-1DFEDD3D21CA Q38874291-F1E8B9E2-9C77-4A90-9F44-09F7FAC585C8 Q38913083-4332D355-CCCC-4BA4-ACC6-87136D3262A0 Q38970585-93997734-05A8-40BE-8525-60DBB321B1A0 Q38996724-3CCF49A1-E485-4189-90CF-048E7DA8EA3D Q39093915-36D84674-9549-4D7F-A16D-BCD99534F270 Q39136762-722B584D-5CE5-4AC1-926D-837B42110B17 Q39200031-DB3992B0-8442-45DB-AC11-25C95849BE0C Q39420466-6DA7DBE9-F225-4F5A-ABA4-A4234A32C886 Q41153847-419B9C3E-3246-4A1C-BE1C-D38EE9EC69F1 Q41168758-B164C729-AE2F-49C9-8433-32B18D35C754 Q41578214-01D48599-2458-4D02-BEB8-275438DE818F Q41770950-8B6C6E57-B605-45FB-AF9E-766234C0CEB1

P2860

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

http://www.wikidata.org/entity/Q39308923

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@en

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@nl

type

label

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@en

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@nl

prefLabel

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@en

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@nl

P1433

Q39308923-19BEF71A-3E90-4433-9F36-86D0C65D3565

P1476

Q39308923-679FA274-52E5-42F1-8639-75C56BD22114

P2093

Q39308923-04541999-DFEC-444F-A4E2-923A72BBC95F

Q39308923-27DC4261-CEF1-4946-90CD-003233127F00

Q39308923-45E10A67-22D6-4B91-8AC2-CD546D46A698

Q39308923-63CD7CC6-C716-4639-BCF9-23EB2DCD30EF

Q39308923-6468C79F-3416-46E8-B47E-77912815A02B

Q39308923-900A9ABF-CA07-42E5-B414-130A27699B3C

Q39308923-B46D6C07-347D-4E21-8482-0A6860D36F84

Q39308923-C353C072-64CE-482E-8097-938B456DF57F

Q39308923-CC52FBDD-4BAE-4E67-9C43-B9AA5ADE5034

Q39308923-D25A53CB-F915-4867-B3B8-6A4D4E17FD59

P2860

Q39308923-01BF35FB-9834-4559-BD4B-FAD6A8D075F2

Q39308923-03B9EAD1-A2A1-414C-989B-1436450128F1

Q39308923-0FC4F8BE-35EB-4B6B-8729-17F5B477EEB4

Q39308923-2034C96C-BEE2-4348-9156-17ACF0CAEC8C

Q39308923-2521A460-6F36-4B85-9641-E1DCCD38FF0D

Q39308923-2D8E80CD-9981-4583-8744-E25D03405245

Q39308923-31579A57-E2C0-44EF-95D3-2FDC93B401BF

Q39308923-3D6815BE-871F-4B95-90CD-DC1C796B05BA

Q39308923-4AC3FAB9-CDED-4213-BB53-080670B2568D

Q39308923-506B91E7-4D69-4D04-BF80-FEFD128C3E3D

P2888

Q39308923-015DB874-0AB3-403D-AA82-9F998889B57C

P304

Q39308923-F4472634-4F29-48EA-8846-3B9381D4EAB8

P31

Q39308923-57941FB6-C396-4C6B-B261-D0D7D6F306D4

P356

Q39308923-ABF3EF37-B595-485A-95DC-5BA23ED411BB

P433

Q39308923-B418646E-7436-4E82-B051-733976F1C92B

P478

Q39308923-343D2CE7-3587-45CC-895A-C5E510A5F56A

P577

Q39308923-00BFD012-6C3E-44C9-9211-27B0DD2FF5F2

P698

Q39308923-F140F824-FAE7-4566-811D-E58A29661F89

P356

P1433

P1476

Marrow stromal cells induce B7 ...... teristics in multiple myeloma.

@en

P2093

A Kondo

http://www.w3.org/2001/XMLSchema#string

E Shinya

http://www.w3.org/2001/XMLSchema#string

H Dong

http://www.w3.org/2001/XMLSchema#string

H Hyodo

http://www.w3.org/2001/XMLSchema#string

H Takahashi

http://www.w3.org/2001/XMLSchema#string

H Tamura

http://www.w3.org/2001/XMLSchema#string

K Dan

http://www.w3.org/2001/XMLSchema#string

K Ogata

http://www.w3.org/2001/XMLSchema#string

K Tamada

http://www.w3.org/2001/XMLSchema#string

L Chen

http://www.w3.org/2001/XMLSchema#string

P2860

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

International staging system for multiple myeloma.

P2888

P304

464-472

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2012.213

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22828443

http://www.w3.org/2001/XMLSchema#string